Overview

USE THE SYSTEMIC METFORMIN IN MELASMA

Status:
Recruiting
Trial end date:
2021-08-01
Target enrollment:
0
Participant gender:
All
Summary
Melasma is a chronic and relapsing acquired dyschromia due to an increased epidermal-melanin unit activity that affects sun-exposed areas mainly in women throughout the reproductive years. It is more common in women, accounting for 90% of all cases.The majority of patients are in third and fourth decades of their life. There are several risk factors that influence its appearance including genetic predisposition,exposure to heat and UV radiation, pregnancy, and exogenous hormones (such as oral contraceptives,thyroid hormones, and hormone replacement therapy). Other factors implicated are phototoxic drugs, anticonvulsant medications,and the use of certain cosmetics. Types of melasma are epidermal, dermal and mixed according to location of melanin.
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Assiut University
Treatments:
Metformin
Criteria
Inclusion Criteria:

1. All patients above 18 years old with melasma.

2. With Fitzpatrick skin phototypes ranging from Type III-V will recruited.

Exclusion Criteria:

1. Pregnant or nursing women.

2. Current use of hormonal birth control medication or any hormonal therapy, Use of
topical hydroquinone within 3 months of study, Use of topical steroids within 1 month
of study, Regular use of tanning parlors and History of laser or dermabrasion to the
face within 9 months of study.

3. Occupation involving primarily outdoor activities.

4. History of kidney dysfunction diabetic (excluded by history and laboratory),
Significant cardiovascular or respiratory disease and any other systemic
diseases(i.e,history of endocrine disorders).

5. patients with poor wound healing, recurrent herpes labialis and current skin infection
(facial warts, molluscum contagiosum, history of hypertrophic scar/keloids, active
dermatosis of atopic, seborrheic or other eczematous type).

6. Photosensitivity,